Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 60 - Any |
| Updated: | 9/23/2018 |
| Start Date: | November 2018 |
| End Date: | November 2025 |
| Contact: | Shannon McCurdy, MD |
| Email: | penncancertrials@emergingmed.com |
| Phone: | 855-216-0098 |
Prospective Analysis of Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
The purpose of this research study is to determine if frailty assessments can be used to
predict how well patients aged 60 years and older will do after chemotherapy or allogeneic
stem cell transplant
predict how well patients aged 60 years and older will do after chemotherapy or allogeneic
stem cell transplant
Eligibility Criteria Arm A:
- Age 60 years or older.
- New diagnosis of Acute Leukemia or MDS, or suspected diagnosis.
- Able to consent to the study.
Eligibility Criteria Arm B:
- Age 60 years or older with a hematologic malignancy.
- Plan to undergo an allogeneic blood or marrow transplantation.
- Able to consent to the study.
We found this trial at
1
site
3400 Civic Center Blvd
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19104
(215) 662-6065
Abramson Cancer Center of the University of Pennsylvania The Abramson Cancer Center of the University...
Click here to add this to my saved trials
